Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 206.00
+2.00 (0.98%)
Inactive · Last trade price on Apr 17, 2026
Ascendis Pharma Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 495.93 | -228.03 | -378.08 | -481.45 | -583.19 | -383.58 |
Depreciation & Amortization | 17.49 | 17.7 | 17.71 | 18.91 | 17.96 | 15.39 |
Stock-Based Compensation | 120.97 | 116.17 | 95.51 | 66.66 | 64.18 | 66.83 |
Other Adjustments | -521.97 | 83.78 | 71.33 | 32.77 | 17.83 | -68.72 |
Change in Receivables | -118.82 | 15.59 | -118.61 | -32.77 | -11.53 | -6.66 |
Changes in Inventories | -21.27 | -5.92 | -86.68 | -78.26 | -55.27 | -75.41 |
Changes in Accounts Payable | 9.34 | -10.37 | 26.97 | 3.55 | 45.94 | 39.19 |
Changes in Income Taxes Payable | -5.46 | -6.68 | -5.51 | -4.47 | -0 | 0.15 |
Changes in Unearned Revenue | 5.92 | 0.13 | -1.2 | -7.08 | 8.65 | 5.2 |
Changes in Other Operating Activities | 78.48 | 71.53 | 72.36 | 14.77 | -0.26 | -10.05 |
Operating Cash Flow | 60.49 | 53.9 | -306.2 | -467.36 | -495.7 | -417.65 |
Capital Expenditures | - | - | - | - | - | -23.7 |
Sale of Property, Plant & Equipment | - | - | 0.95 | 0.05 | - | - |
Purchases of Intangible Assets | -15.49 | -8.49 | -1.43 | -2.44 | -14.49 | -0.53 |
Purchases of Investments | - | - | - | - | -213.84 | -236.23 |
Proceeds from Sale of Investments | - | - | 7.35 | 288.87 | 280.53 | 149.88 |
Other Investing Activities | 0.96 | - | - | - | 9.54 | - |
Investing Cash Flow | -14.54 | -8.49 | 6.88 | 286.47 | 61.73 | -110.58 |
Long-Term Debt Issued | - | - | 134.16 | 136.26 | 503.28 | - |
Long-Term Debt Repaid | -27.47 | -21.96 | -11.37 | -10.44 | -6.36 | - |
Net Long-Term Debt Issued (Repaid) | -27.47 | -21.96 | 122.79 | 125.82 | 496.93 | - |
Issuance of Common Stock | 104.87 | 87.08 | 340.43 | 10.29 | 5.15 | 379.42 |
Repurchase of Common Stock | -51.86 | -17.4 | - | - | -105.31 | -21.61 |
Net Common Stock Issued (Repurchased) | 53.01 | 69.68 | 340.43 | 10.29 | -100.15 | 357.82 |
Other Financing Activities | -8.02 | -11.4 | -19.29 | -1.81 | - | -6.43 |
Financing Cash Flow | 17.52 | 36.33 | 443.93 | 134.29 | 396.77 | 351.39 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -8.58 | -25.24 | 22.77 | -6.01 | 35.69 | 38.59 |
Net Cash Flow | 63.47 | 81.74 | 144.61 | -46.6 | -37.19 | -176.84 |
Free Cash Flow | 60.49 | 53.9 | -306.2 | -467.36 | -495.7 | -441.35 |
Free Cash Flow Growth | 12.23% | - | - | - | - | - |
FCF Margin | 6.99% | 7.48% | -84.20% | -175.23% | -968.65% | -5674.38% |
Free Cash Flow Per Share | 0.97 | 0.89 | -5.29 | -8.30 | -8.84 | -8.06 |
Levered Free Cash Flow | 552.96 | -183.6 | -231.64 | -408.2 | -69.26 | -432.8 |
Unlevered Free Cash Flow | 105.98 | -79.74 | -258.73 | -515.13 | -550.03 | -500.58 |